SAB BIOTHERAPEUTICS, INC.: 10-Q filed 2023-11-13
What SAB BIOTHERAPEUTICS, INC. reported in its quarterly report filed 2023-11-13 (fiscal Q3 2023): 41 published measures, 123 facts as tagged in accession 0000950170-23-063076.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-13
- Fiscal period
- fiscal Q3 2023
- Accession
- 0000950170-23-063076 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SAB BIOTHERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 28,336,297 | USD | |
| At 2022-12-31 | 50,904,927 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 13,080,487 | USD | |
| At 2022-12-31 | 19,846,785 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 15,255,810 | USD | |
| At 2023-06-30 | 19,716,451 | USD | |
| At 2023-03-31 | 24,402,522 | USD | |
| At 2022-12-31 | 31,058,142 | USD | |
| At 2022-09-30 | 30,623,407 | USD | |
| At 2022-06-30 | 37,121,272 | USD | |
| At 2022-03-31 | 41,258,266 | USD | |
| At 2021-12-31 | 38,549,913 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 2,425,480 | USD | |
| At 2022-12-31 | 15,046,894 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -5,102,317 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -19,337,023 | USD | 273 |
| 2023-04-01 to 2023-06-30 | -6,880,886 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -7,353,820 | USD | 90 |
| 2022-07-01 to 2022-09-30 | -7,076,068 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -10,866,209 | USD | 273 |
| 2022-04-01 to 2022-06-30 | -4,775,996 | USD | 91 |
| 2022-01-01 to 2022-03-31 | 985,863 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -11,672,688 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -21,904,487 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 129,290 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 2,048,660 | USD | 273 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 1,267,361 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 1,933,980 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 3,589,708 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 21,743,309 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -863,886 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -7,336,073 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -84,840 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -1,972,270 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -67,206,778 | USD | |
| At 2022-12-31 | -47,869,755 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 52,406,002 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 51,084,636 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 43,030,885 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 43,042,379 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 52,406,002 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 51,084,636 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 43,030,885 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 43,042,379 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.1 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.38 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.16 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.25 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.1 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.38 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.16 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.25 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 20,621,749 | USD | |
| At 2022-12-31 | 23,250,853 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 1,886,841 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 2,045,664 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -5,322,922 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -19,201,549 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -7,807,316 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -21,057,608 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 3,127,711 | USD | |
| At 2022-12-31 | 22,097,453 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 69,700 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 237,405 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 70,626 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 213,885 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 9,210,943 | USD | |
| At 2022-12-31 | 14,993,344 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 1,083,169 | USD | |
| At 2022-12-31 | 3,679,116 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 0 | USD | |
| At 2022-12-31 | 5,556,577 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 6,590,283 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 21,135,529 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 11,397,024 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 42,800,917 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 4,019,718 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 12,217,569 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 7,352,978 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 29,300,405 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 52,319,156 | shares | |
| At 2022-12-31 | 50,394,262 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 87,978,548 | USD | |
| At 2022-12-31 | 84,444,049 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 493,473 | USD | |
| At 2022-12-31 | 1,192,054 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 528,778 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 29,611,117 | USD | |
| At 2022-12-31 | 29,529,375 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 8,989,368 | USD | |
| At 2022-12-31 | 6,278,522 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 702,231 | USD | |
| At 2022-12-31 | 1,493,982 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -5,102,317 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -19,337,023 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -7,076,068 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -10,866,209 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -5,102,317 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -19,337,023 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -7,076,068 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -10,866,209 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 2,570,565 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 8,917,960 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 4,044,046 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 13,500,512 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 960,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 2,730,660 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 890,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 2,270,621 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 220,605 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -135,474 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 731,248 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 10,191,399 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 179,222 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 143,259 | USD | 273 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 118,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 354,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 309,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 930,000 | USD | 273 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -5,556,577 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 4,931,330 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -2,595,947 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 1,025,751 | USD | 273 |
Inspect the source
- Entity
- SAB BIOTHERAPEUTICS, INC. / CIK 0001833214
- Captured
- 2026-09-21T17:30:30.932Z
- SEC response SHA-256
77a9d5e74034d5680bee440489a5722f0205b7102ec23dd33e3ff98bbc2065ac
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001833214.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))